Takashi Kei Kishimoto - Jan 2, 2023 Form 4 Insider Report for SELECTA BIOSCIENCES INC (SELB)

Role
Chief Scientific Officer
Signature
/s/ Matthew Bartholomae, Attorney-in-Fact for Takashi Kei Kishimoto
Stock symbol
SELB
Transactions as of
Jan 2, 2023
Transactions value $
$0
Form type
4
Date filed
1/4/2023, 04:01 PM
Previous filing
Jan 7, 2022
Next filing
Jan 6, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction SELB Common Stock Award $0 +100K +36.48% $0.00 374K Jan 2, 2023 Direct F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction SELB Employee Stock Option (right to buy) Award $0 +475K $0.00 475K Jan 2, 2023 Common Stock 475K $1.13 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each Restricted Stock Unit represents a contingent right to receive one share of common stock, which will vest as to 25% on January 2, 2024. The remainder of the underlying shares will vest in three equal annual installments thereafter so that the underlying shares will be fully vested on January 2, 2027.
F2 Includes 5,747 shares of common stock purchased under the Issuer's Employee Stock Purchase Program during the contribution period between September 1, 2021 and February 28, 2022.
F3 This option vests as to 25% on January 2, 2024. The remainder of the underlying shares will vest in 36 equal monthly installments thereafter.